Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

NCT02318277 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02318277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02318277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
January 5, 2015
Completion date
October 16, 2020
Enrollment
176 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, lung cancer, solid tumors, uc (urothelial cancer)